Paul G. Richardson, MD: A New Era for Patients With Newly Diagnosed Multiple Myeloma?

Posted: Monday, June 13, 2022

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses the implications of phase III findings from the DETERMINATION trial and why they may be critical to improving care for patients with newly diagnosed multiple myeloma. The data showed that lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant and lenalidomide maintenance to disease progression resulted in the longest median progression-free survival reported for each approach, although no survival benefit has been reported as of yet.